title: [Management of chemotherapy-induced anemia in lung cancer].
abstract: BACKGROUND
  The prevalence of chemotherapy-induced anemia in lung cancer is estimated at about 80%.
  
  
  BACKGROUND
  There are currently no specific recommendations for the management of chemotherapy-induced anemia in lung cancer. In this paper, we propose a synthesis of currently existing data in the literature on the management of chemotherapy-induced anemia in general, supplemented with specific data about the efficacy and safety of erythropoietic therapy in lung cancer.
  
  
  CONCLUSIONS
  Better management of chemotherapy-induced anemia improves patient's quality of life and reduces red blood cell transfusion requirement. In the meantime, in respect to currently missing data, thoracic oncologists should develop specific recommendations for the management of chemotherapy-induced anemia in lung cancer, with specific studies in this domain.
  
  
  CONCLUSIONS
  Since the prevalence of chemotherapy-induced anemia in patients with lung cancer is high and has a significant impact on these patients quality of life, a specific prospective management should be implemented as early as possible.
authors.affiliation: Département de pneumologie, CHU de Nancy, 9, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: a.tiotiu@chu-nancy.fr.
authors.forename: A
authors.initials: A
authors.lastname: Tiotiu
authors.affiliation: Département de pneumologie, CHU de Nancy, 9, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: C
authors.initials: C
authors.lastname: Clément-Duchêne
authors.affiliation: Département de pneumologie, CHU de Nancy, 9, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Martinet
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000628:therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D017707:Erythrocyte Transfusion; D005221:Fatigue / Q000209:etiology; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D007501:Iron
keywords: Anemia; Anémie; Cancer bronchique; Chemotherapy; Chimiothérapie; Lung cancer